Note: This section contains information in English only.The drug developer Catalent is set to acquire the privately-owned, gene-therapy oriented Paragon Bioservices in a deal valued at $1.2B, according to the Wall Street Journal's report on Sunday.
Mon, 15 Apr 2019 04:30:17 GMT
Source: Dukascopy Bank SA